{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:39:03Z","timestamp":1761975543194},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004343","name":"3M","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Respiratory Journal"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:p><jats:bold>OBJECTIVE:<\/jats:bold> To compare the systemic safety and efficacy of hydrofluoroalkane beclomethasone dipropionate (HFA\u2010BDP) extra\u2010fine aerosol 800 \u00b5g\/day with chlorofluorocarbon (CFC)\u2010BDP 1500 \u00b5g\/day.<\/jats:p><jats:p><jats:bold>DESIGN:<\/jats:bold> Six\u2010month, randomized, parallel\u2010group, double\u2010blind, double\u2010dummy study.<\/jats:p><jats:p><jats:bold>PATIENTS:<\/jats:bold> Patients (n=141) with moderate to severe asthma adequately controlled by CFC\u2010BDP 1000 \u00b5g\/day to 2000 \u00b5g\/day.<\/jats:p><jats:p><jats:bold>INTERVENTIONS:<\/jats:bold> Patients received CFC\u2010BDP 1500 \u00b5g\/day during a two\u2010week run\u2010in period and were then randomized to either HFA\u2010BDP (n=70) or CFC\u2010BDP (n=71).<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Similar proportions of HFA\u2010BDP and CFC\u2010BDP patients had a 24 h urinary free cortisol values below the reference range at month 6 (15% versus 25%, P=0.35). Measures of adrenocorticotrophic hormone stimulation and morning plasma cortisol levels were also similar in each group. The frequency of skin bruising and oral candidiasis was low for both treatments. No change in intraocular pressure was reported for either treatment. Pulmonary function was similar in both groups; however, the onset of the first asthma exacerbation or increased asthma symptoms tended to be earlier for CFC\u2010BDP than for HFA\u2010BDP (P=0.076); 27% of CFC\u2010BDP patients reported increased asthma symptoms, compared with 14% of HFA\u2010BDP patients (P=0.095).<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> HFA\u2010BDP 800 \u00b5g\/day has a systemic adverse event profile comparable to that of CFC\u2010BDP 1500 \u00b5g\/day, and further control of asthma symptoms may be achieved after a switch from CFC\u2010BDP 1500 \u00b5g\/day to HFA\u2010BDP 800 \u00b5g\/day.<\/jats:p>","DOI":"10.1155\/2004\/823084","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T08:05:13Z","timestamp":1458029113000},"page":"123-130","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Efficacy of HFA\u2010134a Beclomethasone Dipropionate Extra\u2010Fine Aerosol over Six Months"],"prefix":"10.1155","volume":"11","author":[{"given":"Louis-Philippe","family":"Boulet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Cartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Lariv\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Laviolette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,5,3]]},"container-title":["Canadian Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2004\/823084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2004\/823084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T09:35:30Z","timestamp":1722332130000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2004\/823084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1155\/2004\/823084"],"URL":"https:\/\/doi.org\/10.1155\/2004\/823084","archive":["Portico"],"relation":{},"ISSN":["1198-2241","1916-7245"],"issn-type":[{"type":"print","value":"1198-2241"},{"type":"electronic","value":"1916-7245"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"2004-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}